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Purpose/Objective: This is the first study of treatment with 
hyperthermia associated with standard cancer treatment 
(Radiotherapy +/- Chemotherapy), carried out in Andalusia 
the south of Spain. 
Materials and Methods: The study’s objectives were to 
analyze the clinical benefits, response to treatment, 
treatment feasibility and comfort with hyperthermia 
associated with standard oncological treatment within the 
public health system in Andalusia. Secondary objectives 
analyze survival, quality of life, overall toxicity (general and 
specific oncological hyperthermia). The design is a case-
control study, applying hyperthermia treatment (10 sessions/ 
2-3 per week), with standard treatment of Radiotherapy, 
Chemotherapy or a combination of both, in patients with 
primary tumors or metastasis ones treated with radical or 
palliative treatments with a life expectancy of at least of 6 
months. Tumor locations are: Cervix, prostate, bladder, 
pancreas, non surgical head and neck tumors, brain tumors, 
preoperative rectal Cancer, advanced not surgical breast 
tumors, lung cancer. 
Results: We present preliminary data from 63 patients (31 
from the Juan Ramón Jiménez Hospital and 32 from the 
Carlos Haya Hospital), who received 10 sessions of high deep 
Hyperthermia, 2-3 times per week, 1 hour per session and a 
radiofrequency power between 150w and 400w according to 
the location of the tumor, associated with the standard 
cancer treatment (RT +/- CH). There are 38 men and 22 
women, with a mean age 59 (34-80), the majority were brain 
or head and neck tumors in Carlos Haya Hospital, and rectal, 
prostate an breast tumors in Hospital Juan Ramón Jimenez. 
The intention of the treatment was curative 48.3%, 
neoadyuvante 23.4% and palliative 28.3%. Concerning the 
toxicity, there has been a burning type grade I toxicity in 
36.3% of the cases and 66.6% of the patients had no toxicity. 
One patient reported pain/ pressure in the treatment area, 
grade I (in an ulcerated breast). Despite the mild toxicity 
presented the patient’s satisfaction with the treatment was 
very satisfactory in 81.2% of patients and acceptable in 
18.8%. The majority of the patients (83%) completed the 
Hyperthermia treatment as prescribed. 
Conclusions: The treatment is feasible and comfortable in 
81.2% of patients in a public environment health hospital, 
with mild toxicity in 33% of the cases and the rest without no 
toxicity. It is essential a proper selection of the cases to be 
treated with Hyperthermia to expect good results with this 
treatment. 
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Purpose/Objective: To analyse survival and patterns of 
failure of patients with glioblastoma (GBM) treated with 
radical chemo-radiotherapy in the Anglia Cancer Network. 
Materials and Methods: 205 patients treated with radical 
chemo-radiotherapy during January 2006 to March 2012 were 
identified. All patients had been treated to a dose of 60 Gy in 
30 fractions in two-phases with concomitant and adjuvant 
temozolomide. Postoperative resection cavity with residual 
tumour on T1W gadolinium-enhanced MRI scan was outlined 
(GTV) and a margin of 25 mm was added to obtain CTV50 (CTV 
receiving 50 Gy) and a margin of 15 mm was added to obtain 
CTV60. A 5 mm margin was added to CTV50 and CTV60 to define 
corresponding PTVs. 124 patients had MRI confirmed 
relapse/progression. T1W-Gd MRI data sets showing recurrent 
tumour in patients (n=34) treated at one of the Anglia Cancer 
Network Hospitals (Norfolk and Norwich University Hospital) 
were co-registered with planning CT scan to delineate 
recurrent tumour and to correlate the pattern of failure with 
the actual radiation dose delivered (Figure 1A-C). Overall 
survival was calculated using the Kaplan-Meier method. 
Results: Median follow-up of 205 patients treated with 
radical chemo-radiotherapy was 37.7 months. The median 
survival was 16.5 months (95% CI 14.7 – 18.3). The 2-year 
overall survival (OS) was 32%, 3-year OS 17%, and 5-year OS 
12%. The median OS of patients (n=34) included in the 
patterns-of-failure study was 17.7 months (95% CI: 13.4-22.1) 
and median progression-free interval was 7.8 months (95% CI: 
6.3-8.6). In 25 out of 34 patients (74%), treatment failure 
developed within a region previously irradiated to 57 Gy (D57) 
(figure 1D). In 7 patients treatment failure developed within 
D>50 (area received >50 Gy), where on average 3% of recurrent 
tumour volume received 50-57Gy and 97% received >57 Gy. In 
one patient, 54% of recurrent tumour volume received >50 Gy 
while, 42% received <30 Gy. One patient had a recurrent 
tumour outside D30 (area received 30 Gy). Further analysis of 
patterns-of-failure in the remaining cohort is continuing. 
 
  
 
Conclusions: The survival of patients in this series is similar 
to that reported in the Stupp study1. Based on this small 
cohort, there may be at least three different patterns of 
failure: tumour recurrence within the high-dose radiotherapy 
(>57 Gy) region continues to be the predominant pattern 
(74%). In >20% of patients, treatment failure developed at 
the edge of the high-dose radiotherapy region (50-57Gy) 
suggesting the need for incorporation of better imaging 
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techniques such as DTI to delineate tumour volume. <5% 
patients develop disease recurrence predominantly in the 
low-dose radiotherapy (<30 Gy) region. Identification and 
prediction of dosimetrically distinct patterns of treatment-
failure that can be correlated with specific molecular profiles 
may be useful to individualize and thereby, improve survival 
of glioblastoma. 
Reference:1. Stupp R, Hegi ME, Mason WP et al. Lancet 
Oncol. 2009; 10:459 
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Purpose/Objective: Analyze the toxicity of and response to 
carbon ion radiotherapy (CIRT) in patients diagnosed with 
malignant mucosal melanoma (MMM) in the upper 
aerodigestive tract of the head and neck area inoperable, 
with macroscopic residual/relapse after surgery or in patients 
that refused surgery. 
Materials and Methods: We analyzed data coming from 
patients with an MMM diagnosis in the head and neck area 
treated at CNAO from May 2013 to October 2014 with carbon 
ion radiotherapy at a total dose of 68,8 GyE in 16 fractions. 
The toxicity was evaluated in the scale CTCAE v.4.0 and the 
response to the disease with MRI every three months from 
CIRT. 
Results: We treated 8 patients (average age 72 years-old, 
range from 48 to 86) with MMM in the following areas: 
nasopharynx (1 patient), lacrimal duct (1 patient), nasal 
cavity (4 patients), mouth (1 patient), oropharynx (1 
patient). 3 patients were treated with macroscopic residual 
after surgery, 2 patients after post-surgical relapse with 
positive margins, 3 patients only with CIRT. Average GVT was 
31.47 cc (range 7.76-84.23 cc). 2 patients received systemic 
therapy pre-CIRT (1 out of 2 also post-CIRT). In the course of 
treatment, toxicity appeared acceptable (≤ G2 in 7 patients, 
G3 mucositis in 1 patient). The mean follow-up was 8 months 
(range 3-12). 3 months follow-up was available for 5 patients 
(1 patient completed CIRT one month ago, 2 patients died at 
2 and 3 months after CIRT for the progression of distant 
disease) and showed low grade acute toxicity (G0 in 4 
patients, G1 in 1 patient); at 3 months response evaluated 
with RECIST was CR in 2 patients and PR in 3 patients. 
Follow-up at the 6 months (available for 4 patients) 
confirmed low intermediate toxicity (G1 in all the patients), 
partial response (PR) in 3 patients and complete response 
(CR) in 1 patient. Follow-up at 9 months was available for 4 
patients, the highest toxicity was G2 in 1 patients, PR in 1 
patient and CR in 3 patients. Follow-up at 12 months was 
available only for 1 patient, with confirmed CR and toxicity 
G1. Progression disease took place in 2 patients, respectively 
at 0 and 1 months after CIRT (in both cases distant PD in 
absence of local PD). 
Conclusions: Recommended treatment for patients with MMM 
in the head and neck area is surgery followed by adjuvant 
radiotherapy. In the event of macroscopic residual or not 
resectable disease, preliminary results observed at CNAO 
confirm that CIRT guarantee good local control, allowing high 
dose on complex volume and in the proximity of critical 
organs with very low 
These data are preliminary; larger patient number and longer 
follow up are needed. 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the 
most common and malignant brain tumor in adults. 
Aggressive multimodal treatment using surgery followed by 
radiotherapy and chemotherapy extends the median survival 
of GBM patients to approximately one year after diagnosis. 
Treatment is not curative because of the intrinsic and 
acquired radiation resistance of a subpopulation of tumor 
cells. Notch inhibition has been shown to impair the 
tumorigenic capacity of these cells as well as enhance their 
sensitivity towards radiation. Therefore, we investigated if a 
highly potent and clinically approved Notch pathway inhibitor 
improves tumor control when combined with radiotherapy 
and chemotherapy in an orthotopic GBM mouse model.  
Materials and Methods: To investigate combinations between 
standard of care treatment and Notch inhibitors, we used a 
three dimensional spheroid assay from commercially 
available and primary glioma cell lines in which spheroid 
volume growth delay can be quantitatively monitored in 
individual spheroids. In addition, we assessed the expression 
of the putative glioma stem cell marker CD133 performing 
flow cytometry. Furthermore, therapeutic efficacy was 
evaluated in an orthotopic glioma tumor model wherein 
tumor progression was evaluated using bioluminescence (BLI) 
and contrast-enhanced micro-computed tomography (CT) 
imaging and confirmed using histopathological analysis. 
Dedicated small animal treatment planning software (SmART-
Plan) was used to create irradiation plans to deliver a 
conformal dose of 8Gy to the tumor with minimal normal 
tissue exposure. A small animal precision irradiation platform 
(PXI, XRAD 225Cx, CT, USA) was used for micro-CT imaging 
and radiation delivery. 
Results: Notch blockade alone did not affect the sphere 
volume compared to control, whereas combination treatment 
with radiation resulted in a substantial spheroid growth delay 
(p=0.004). Radiation treatment enhanced the expression of 
the stem cell marker CD133, while Notch blockade reduced 
CD133 expression. We found a strong correlation between CT 
and BLI imaging of tumor growth in vivo (Pearson coefficient 
(r)=0.85, p=0.001). The potential of Notch inhibition 
